{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:15Z","timestamp":1707524535593},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,30]]},"DOI":"10.7759\/cureus.21745","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T03:00:07Z","timestamp":1643598007000},"source":"Crossref","is-referenced-by-count":0,"title":["Application of Anticonvulsants, Antiepileptic Drugs, and Vitamin C in the Treatment and Analysis of Batten Disease"],"prefix":"10.7759","author":[{"given":"Shreya","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hetal","family":"Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Institute of Neurological Disorders and Stroke. Batten disease fact sheet. . (2021). Accessed: January 18, 2022: https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Batten-Disease-Fact-Sheet."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.78.926.736","article-title":"Management of motor neurone disease","volume":"78","author":"Howard RS","year":"2002","unstructured":"Howard RS, Orrell RW. Management of motor neurone disease. Postgrad Med J. 2002, 78:736-41. 10.1136\/pmj.78.926.736","journal-title":"Postgrad Med J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.08.008","article-title":"Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes","volume":"50","author":"Jadav RH","year":"2014","unstructured":"Jadav RH, Sinha S, Yasha TC, et al.. Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol. 2014, 50:85-95. 10.1016\/j.pediatrneurol.2013.08.008","journal-title":"Pediatr Neurol"},{"key":"ref4","unstructured":"What Is Batten Disease?. (2021). Accessed. January 18, 2022: https:\/\/www.webmd.com\/children\/batten-disease."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320420434","article-title":"English setter model and juvenile ceroid-lipofuscinosis in man","volume":"42","author":"Koppang N","year":"1992","unstructured":"Koppang N. English setter model and juvenile ceroid-lipofuscinosis in man. Am J Med Genet. 1992, 42:599-604. 10.1002\/ajmg.1320420434","journal-title":"Am J Med Genet"},{"key":"ref6","unstructured":"FDA approves BioMarin's Batten Disease Drug. Cost per year is $702,000. (2017). Accessed. January 18, 2022: https:\/\/www.chemdiv.com\/company\/media\/pharma-news\/2017\/fda-approves-biomarins-batten-disease-drug-cost-per-year-70200...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-016-9986-1","article-title":"Flunarizine rescues reduced lifespan in CLN3 triple knock-out Caenorhabditis elegans model of batten disease","volume":"40","author":"Kwon YJ","year":"2017","unstructured":"Kwon YJ, Falk MJ, Bennett MJ. Flunarizine rescues reduced lifespan in CLN3 triple knock-out Caenorhabditis elegans model of batten disease. J Inherit Metab Dis. 2017, 40:291-6. 10.1007\/s10545-016-9986-1","journal-title":"J Inherit Metab Dis"},{"key":"ref8","unstructured":"Anticonvulsants for bipolar disorder. (2021). Accessed. January 19, 2022: https:\/\/www.webmd.com\/bipolar-disorder\/guide\/anticonvulsant-medication."},{"key":"ref9","unstructured":"The Royal Children's Hospital Melbourne. Antiepileptic medications. Accessed: January 19, 2022: https:\/\/www.rch.org.au\/neurology\/patient_information\/antiepileptic_medications\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2015.00397","article-title":"Vitamin C in health and disease: its role in the metabolism of cells and redox state in the brain","volume":"6","author":"Figueroa-M\u00e9ndez R","year":"2015","unstructured":"Figueroa-M\u00e9ndez R, Rivas-Arancibia S. Vitamin C in health and disease: its role in the metabolism of cells and redox state in the brain. Front Physiol. 2015, 6:397. 10.3389\/fphys.2015.00397","journal-title":"Front Physiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010299","article-title":"Occipital epilepsy versus progressive myoclonic epilepsy in a patient with continuous occipital spikes and photosensitivity in electroencephalogram: a case report","volume":"97","author":"Lv Y","year":"2018","unstructured":"Lv Y, Zhang N, Liu C, Shi M, Sun L. Occipital epilepsy versus progressive myoclonic epilepsy in a patient with continuous occipital spikes and photosensitivity in electroencephalogram: a case report. Medicine (Baltimore). 2018, 97:e0299. 10.1097\/MD.0000000000010299","journal-title":"Medicine (Baltimore)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2518-14.2014","article-title":"An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis","volume":"34","author":"Macauley SL","year":"2014","unstructured":"Macauley SL, Wong AM, Shyng C, et al.. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci. 2014, 34:13077-82. 10.1523\/JNEUROSCI.2518-14.2014","journal-title":"J Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-015-0359-4","article-title":"Congenital CLN disease in two siblings","volume":"165","author":"Meyer S","year":"2015","unstructured":"Meyer S, Yilmaz U, Kim YJ, et al.. Congenital CLN disease in two siblings. Wien Med Wochenschr. 2015, 165:210-3. 10.1007\/s10354-015-0359-4","journal-title":"Wien Med Wochenschr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-2199-9_6","article-title":"Vitamin C transport and its role in the central nervous system","volume":"56","author":"May JM","year":"2012","unstructured":"May JM. Vitamin C transport and its role in the central nervous system. Subcell Biochem. 2012, 56:85-103. 10.1007\/978-94-007-2199-9_6","journal-title":"Subcell Biochem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000145836.72059.3b","article-title":"Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders","volume":"63","author":"Pearce DA","year":"2004","unstructured":"Pearce DA, Atkinson M, Tagle DA. Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology. 2004, 63:2001-5. 10.1212\/01.wnl.0000145836.72059.3b","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973676","article-title":"Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL)","volume":"28","author":"Aberg L","year":"1997","unstructured":"Aberg L, Heiskala H, Vanhanen SL, Himberg JJ, Hosking G, Yuen A, Santavuori P. Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL). Neuropediatrics. 1997, 28:77-9. 10.1055\/s-2007-973676","journal-title":"Neuropediatrics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00782.x","article-title":"Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis","volume":"40","author":"Aberg L","year":"1999","unstructured":"Aberg L, Kirveskari E, Santavuori P. Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia. 1999, 40:796-9. 10.1111\/j.1528-1157.1999.tb00782.x","journal-title":"Epilepsia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/088307389400900107","article-title":"Valproate-associated acute pancreatitis in a child with neuronal ceroid lipofuscinosis","volume":"9","author":"Talwar D","year":"1994","unstructured":"Talwar D. Valproate-associated acute pancreatitis in a child with neuronal ceroid lipofuscinosis. J Child Neurol. 1994, 9:36-7. 10.1177\/088307389400900107","journal-title":"J Child Neurol"},{"key":"ref19","unstructured":"Harvard Health Publishing. By the way, doctor: What's the right amount of vitamin C for me?. (2020). Accessed: January 19, 2022: https:\/\/www.health.harvard.edu\/staying-healthy\/by-the-way-doctor-whats-the-right-amount-of-vitamin-c-for-me."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.10.013","article-title":"Hippocampal volumes in juvenile neuronal ceroid lipofuscinosis: a longitudinal magnetic resonance imaging study","volume":"50","author":"Tokola AM","year":"2014","unstructured":"Tokola AM, Salli EK, \u00c5berg LE, Autti TH. Hippocampal volumes in juvenile neuronal ceroid lipofuscinosis: a longitudinal magnetic resonance imaging study. Pediatr Neurol. 2014, 50:158-63. 10.1016\/j.pediatrneurol.2013.10.013","journal-title":"Pediatr Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s0387-7604(01)00231-5","article-title":"Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis","volume":"23","author":"Veneselli E","year":"2001","unstructured":"Veneselli E, Biancheri R, Buoni S, Fois A. Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis. Brain Dev. 2001, 23:306-11. 10.1016\/s0387-7604(01)00231-5","journal-title":"Brain Dev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2019.05.001","article-title":"Perampanel attenuates myoclonus in a patient with neuronal ceroid lipofuscinoses type 2 disease","volume":"41","author":"Wong LC","year":"2019","unstructured":"Wong LC, Hsu CJ, Lee WT. Perampanel attenuates myoclonus in a patient with neuronal ceroid lipofuscinoses type 2 disease. Brain Dev. 2019, 41:817-9. 10.1016\/j.braindev.2019.05.001","journal-title":"Brain Dev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-197401000-00001","article-title":"Presidential address: studies in the neuronal ceroid-lipofuscinoses","volume":"33","author":"Zeman W","year":"1974","unstructured":"Zeman W. Presidential address: studies in the neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol. 1974, 33:1-12. 10.1097\/00005072-197401000-00001","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/BF02990136","article-title":"Selenium in chronic neurologic diseases. Multiple sclerosis and Batten's disease","volume":"15","author":"Clausen J","year":"1988","unstructured":"Clausen J, Jensen GE, Nielsen SA. Selenium in chronic neurologic diseases. Multiple sclerosis and Batten's disease. Biol Trace Elem Res. 1988, 15:179-203. 10.1007\/BF02990136","journal-title":"Biol Trace Elem Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320310629","article-title":"Experience over 17 years with antioxidant treatment in Spielmeyer-Sj\u00f6gren disease","volume":"5","author":"Santavuori P","year":"1988","unstructured":"Santavuori P, Heiskala H, Westermarck T, Sainio K, Moren R. Experience over 17 years with antioxidant treatment in Spielmeyer-Sj\u00f6gren disease. Am J Med Genet Suppl. 1988, 5:265-74. 10.1002\/ajmg.1320310629","journal-title":"Am J Med Genet Suppl"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1985.tb03178.x","article-title":"Antioxidant treatment in Spielmeyer-Sj\u00f6gren's disease","volume":"71","author":"Santavuori P","year":"1985","unstructured":"Santavuori P, Westermarck T, Rapola J, Pohja P, Moren R, Lappi M, Vuonnala U. Antioxidant treatment in Spielmeyer-Sj\u00f6gren's disease. Acta Neurol Scand. 1985, 71:136-45. 10.1111\/j.1600-0404.1985.tb03178.x","journal-title":"Acta Neurol Scand"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1023\/a:1020613631353","article-title":"Normal ascorbic acid in cerebrospinal fluid of patients with infantile neuronal ceroid-lipofuscinosis","volume":"14","author":"Sass JO","year":"1999","unstructured":"Sass JO, Skladal D, Brunner-Krainz M. Normal ascorbic acid in cerebrospinal fluid of patients with infantile neuronal ceroid-lipofuscinosis. Metab Brain Dis. 1999, 14:67-70. 10.1023\/a:1020613631353","journal-title":"Metab Brain Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04608.x","article-title":"Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis","volume":"41","author":"Aberg LE","year":"2000","unstructured":"Aberg LE, B\u00e4ckman M, Kirveskari E, Santavuori P. Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia. 2000, 41:1296-302. 10.1111\/j.1528-1157.2000.tb04608.x","journal-title":"Epilepsia"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320420421","article-title":"Neurology of the neuronal ceroid-lipofuscinoses: late infantile and juvenile types","volume":"42","author":"Boustany RM","year":"1992","unstructured":"Boustany RM. Neurology of the neuronal ceroid-lipofuscinoses: late infantile and juvenile types. Am J Med Genet. 1992, 42:533-5. 10.1002\/ajmg.1320420421","journal-title":"Am J Med Genet"},{"key":"ref30","article-title":"On the application of cannabis in paediatrics and epileptology","volume":"25","author":"Lorenz R","year":"2004","unstructured":"Lorenz R. On the application of cannabis in paediatrics and epileptology. Neuro Endocrinol Lett. 2004, 25:40-4.","journal-title":"Neuro Endocrinol Lett"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/08830738020170011201","article-title":"Progressive myoclonic epilepsies","volume":"17","author":"Conry JA","year":"2002","unstructured":"Conry JA. Progressive myoclonic epilepsies. J Child Neurol. 2002, 17:S80-4. 10.1177\/08830738020170011201","journal-title":"J Child Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2015.06.007","article-title":"Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression","volume":"63","author":"Zhou R","year":"2015","unstructured":"Zhou R, Lu Y, Han Y, et al.. Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression. Prog Neuropsychopharmacol Biol Psychiatry. 2015, 63:110-8. 10.1016\/j.pnpbp.2015.06.007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04763-1","article-title":"Successful treatment of cannabinoid administration against refractory epilepsy in Batten disease: a case report","volume":"42","author":"Georgiou F","year":"2021","unstructured":"Georgiou F, Maghsoudlou P, Loukaidis P, Markoullaki D, Giorgi C, Christodoulou I, Matsentidou C. Successful treatment of cannabinoid administration against refractory epilepsy in Batten disease: a case report. Neurol Sci. 2021, 42:1203-6. 10.1007\/s10072-020-04763-1","journal-title":"Neurol Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00710270","article-title":"Low erythrocyte plasmalogen and plasma docosahexaenoic acid (DHA) in juvenile neuronal ceroid-lipofuscinosis (JNCL)","volume":"16","author":"Kohlsch\u00fctter A","year":"1993","unstructured":"Kohlsch\u00fctter A, Schade B, Bl\u00f6mer B, H\u00fcbner C. Low erythrocyte plasmalogen and plasma docosahexaenoic acid (DHA) in juvenile neuronal ceroid-lipofuscinosis (JNCL). J Inherit Metab Dis. 1993, 16:299-304. 10.1007\/BF00710270","journal-title":"J Inherit Metab Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.02.011","article-title":"Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease)","volume":"23","author":"Larsen EP","year":"2014","unstructured":"Larsen EP, Ostergaard JR. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). Seizure. 2014, 23:429-34. 10.1016\/j.seizure.2014.02.011","journal-title":"Seizure"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1579784","article-title":"Considering valproate as a risk factor for rapid exacerbation of complex movement disorder in progressed stages of late-infantile CLN2 disease","volume":"47","author":"Johannsen J","year":"2016","unstructured":"Johannsen J, Nickel M, Schulz A, Denecke J. Considering valproate as a risk factor for rapid exacerbation of complex movement disorder in progressed stages of late-infantile CLN2 disease. Neuropediatrics. 2016, 47:194-6. 10.1055\/s-0036-1579784","journal-title":"Neuropediatrics"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1988.tb10770.x","article-title":"Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability","volume":"77","author":"Kohlsch\u00fctter A","year":"1988","unstructured":"Kohlsch\u00fctter A, Laabs R, Albani M. Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability. Acta Paediatr Scand. 1988, 77:867-72. 10.1111\/j.1651-2227.1988.tb10770.x","journal-title":"Acta Paediatr Scand"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/01.NPR.0000337191.77316.82","article-title":"Treatment of seizures in a patient with Batten's disease","volume":"33","author":"Patel NC","year":"2008","unstructured":"Patel NC, Davenport RD, Patel HN. Treatment of seizures in a patient with Batten's disease. Nurse Pract. 2008, 33:6-9. 10.1097\/01.NPR.0000337191.77316.82","journal-title":"Nurse Pract"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320310623","article-title":"Decreased membrane fluidity of lymphocytes from patients with juvenile neuronal ceroid-lipofuscinosis","volume":"5","author":"Kohlsch\u00fctter A","year":"1988","unstructured":"Kohlsch\u00fctter A, H\u00fcbner C, G\u00e4rtner J. Decreased membrane fluidity of lymphocytes from patients with juvenile neuronal ceroid-lipofuscinosis. Am J Med Genet Suppl. 1988, 5:203-7. 10.1002\/ajmg.1320310623","journal-title":"Am J Med Genet Suppl"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-020-02747-1","article-title":"Batten disease and perioperative complications: a retrospective descriptive study","volume":"34","author":"Yamaguchi Y","year":"2020","unstructured":"Yamaguchi Y, Lyman R, De Los Reyes E, Kim SS, Uffman JC, Tobias JD. Batten disease and perioperative complications: a retrospective descriptive study. J Anesth. 2020, 34:342-7. 10.1007\/s00540-020-02747-1","journal-title":"J Anesth"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320570222","article-title":"Free radicals, anticonvulsants, and the neuronal ceroid-lipofuscinoses","volume":"57","author":"Maertens P","year":"1995","unstructured":"Maertens P, Dyken P, Graf W, Pippenger C, Chronister R, Shah A. Free radicals, anticonvulsants, and the neuronal ceroid-lipofuscinoses. Am J Med Genet. 1995, 57:225-8. 10.1002\/ajmg.1320570222","journal-title":"Am J Med Genet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2010.09.004","article-title":"Screening for calcium channel modulators in CLN3 siRNA knock down SH-SY5Y neuroblastoma cells reveals a significant decrease of intracellular calcium levels by selected L-type calcium channel blockers","volume":"1810","author":"An Haack K","year":"2011","unstructured":"An Haack K, Narayan SB, Li H, Warnock A, Tan L, Bennett MJ. Screening for calcium channel modulators in CLN3 siRNA knock down SH-SY5Y neuroblastoma cells reveals a significant decrease of intracellular calcium levels by selected L-type calcium channel blockers. Biochim Biophys Acta. 2011, 1810:186-91. 10.1016\/j.bbagen.2010.09.004","journal-title":"Biochim Biophys Acta"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84863-application-of-anticonvulsants-antiepileptic-drugs-and-vitamin-c-in-the-treatment-and-analysis-of-batten-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:56Z","timestamp":1707507416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84863-application-of-anticonvulsants-antiepileptic-drugs-and-vitamin-c-in-the-treatment-and-analysis-of-batten-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.21745","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,30]]}}}